Develops and commercializes innovative treatments for attention deficit/hyperactivity disorder (ADHD) and other neuropsychiatric disorders.
Cingulate Inc., a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, specializes in advancing product candidates aimed at addressing attention-deficit/hyperactivity disorder (ADHD). At the forefront of its development efforts are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both currently undergoing Phase 3 clinical trials. These lead compounds hold promise for providing effective therapeutic options for individuals affected by ADHD, leveraging their respective mechanisms of action to manage symptoms effectively.
In addition to its focus on ADHD treatments, Cingulate Inc. is actively pursuing the development of CTx-2103, a product candidate designed specifically for the treatment of anxiety disorders. This initiative underscores the company's commitment to addressing a broad spectrum of neurological and psychiatric conditions through innovative therapeutic approaches.
Founded in 2012, Cingulate Inc. has rapidly positioned itself as a leader in the biopharmaceutical industry, driven by a dedication to scientific innovation and patient-centric research. With a robust pipeline and strategic focus on advancing novel therapies, the company continues to expand its portfolio to meet the evolving needs of patients worldwide affected by ADHD and related disorders.